IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Earum Pharmaceuticals IPO is a Fixed Price listing on BSE SME exchange. The company is based in Ahmedabad and caters to Pharmaceutical sector. Hem Securities is the merchant banker of Earum Pharmaceuticals IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 9th April 2019.
Earum Pharmaceuticals IPO posted revenues of ₹ 46.00 crores and PAT of ₹ 1.16 crores in FY19 on annualised basis.
Revenue:
₹ 45.99 Cr.
EBITDA Margin:
5.57
% 
Net Worth: ₹ 5.07 Cr.
Market Capitalisation:
[●]
P/E:
19.00 times
P/BV: [●]
EV/EBITDA: [●]
Financial results of Earum Pharmaceuticals IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Dec-18 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 27.41 | 20.52 | 11.08 | 8.78 | |
| Net Worth | 5.07 | 4.21 | 1.52 | 1.36 | |
| Total Debt | 7.89 | 7.22 | 2.08 | 1.89 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
34.49
45.99 |
35.43 | 23.33 | 18.56 | |
EBITDA
EBITDA on annualised basis |
1.92
2.56 |
1.46 | 0.31 | 0.47 | |
PAT
PAT on annualised basis |
0.86
1.15 |
0.85 | 0.15 | 0.09 | |
Earum Pharmaceuticals IPO PAT Margin is 2.49 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Earum Pharmaceuticals IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Dec-18 | FY18 | FY17 | FY16 |
|---|---|---|---|---|
| EBITDA Margin (%) | 5.57 | 4.12 | 1.33 | 2.53 |
| PAT Margin (%) | 2.49 | 2.40 | 0.64 | 0.48 |
| EPS (₹) | 2.00 | 3.50 | 1.06 | 0.88 |
| ROE (%) | 16.96 | 20.19 | 9.87 | 6.62 |
| ROCE (%) | [●] | [●] | [●] | [●] |
| ROA (%) | 3.14 | 4.14 | 1.35 | 1.03 |
| Debt to Equity | 1.56 | 1.71 | 1.37 | 1.39 |
The market Capitalisation of Earum Pharmaceuticals IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Earum Pharmaceuticals IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Earum Pharmaceuticals IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Earum Pharmaceuticals IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Earum Pharmaceuticals IPO has a Price-to-Earnings (PE) ratio of 19.00 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Earum Pharmaceuticals IPO reported revenue of ₹ 46.00 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Earum Pharmaceuticals IPO provide insights into sales growth, market demand, and business scalability.
Earum Pharmaceuticals recorded an EBITDA of ₹ 2.56 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Earum Pharmaceuticals Profit After Tax (PAT) is ₹ 1.15 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 45.99 Cr.
EBITDA Margin:
5.57
%
Net Worth: ₹ 5.07 Cr.
Market Capitalisation:
[●]
P/E:
19.00 times
P/BV: [●]
EV/EBITDA: [●]
Earum Pharmaceuticals operates in Pharmaceutical and . The Issue is listed on BSE SME in Jul, 2019. Earum Pharmaceuticals IPO size was 6.65 with Issue price of 36.00 .
Merchant Banker(s) of Earum Pharmaceuticals IPO: Hem Securities Limited
Earum Pharmaceuticals IPO subscription was 1.60 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Earum Pharmaceuticals IPO listed at a listing price of 36.05 against the offer price of 36.00.
The current market price of Earum Pharmaceuticals is 1.43.
Why Us?
